Cognitive Impairment in Depression: Psychological Models and Clinical Issues

Murphy, Fionnuala C.; Sahakian, Barbara J.; Carroll, Robin E.

doi:10.1159/000058878

Cited by 11 publications

(7 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Again, patient numbers were small and some treatments and combinations were not represented. Evidence is lacking about the efficacy of specific psychotherapies in severely ill hospitalized patients (Persons et al, 1996;Thase and Friedman, 1999); in these patients cognitive deficits may be expected to impair ability to engage with psychological treatment (Murphy et al, 1998).…”

Section: For Mild To Moderate Severity (Ia-ib) the Efficacy Of Non-dmentioning

confidence: 99%

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines

2000

View full text Add to dashboard Cite

A revision of the British Association for Psychopharmacology guidelines for treating depressive disorders with antidepressants was undertaken in order to specify the scope and target of the guidelines and to update the recommendations based explicitly on the available evidence. A consensus meeting, involving experts in depressive disorders and their treatment, reviewed key areas and considered the strength of evidence and clinical implications. The guidelines were drawn up after extensive feedback from participants and interested parties. A literature review is given which identifies the quality of evidence followed by recommendations, the strength of which are based on the level of evidence. The guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing, management when initial treatment fails, continuation treatment, maintenance treatment to prevent recurrence and stopping treatment.

show abstract

Section: For Mild To Moderate Severity (Ia-ib) the Efficacy Of Non-dmentioning

confidence: 99%

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines

2000

View full text Add to dashboard Cite

show abstract

“…An important and comprehensive review by Miller (1975) challenged this belief by suggesting that even mild depression can be associated with pronounced deficits on cognitive, motor, perceptual and communication tasks. Many studies have since demonstrated the presence of wide-ranging neuropsychological deficits in depressed patients (Weingartner et al 1981;Beats et al 1996;Elliott et al 1996;Murphy et al 1998). However, a contentious issue that remains is whether depressed patients show a specific and consistent profile of impairment.…”

Section: Introductionmentioning

confidence: 99%

The effects of tryptophan depletion on cognitive and affective processing in healthy volunteers

et al. 2002

View full text Add to dashboard Cite

The present data indicate that serotonergic factors may be more involved in the disrupted inhibitory and emotional processing characteristic of depression than in other aspects of executive function, such as planning ability. These findings support the recent proposal that serotonergic manipulation may have greater effects on tasks mediated by frontal circuitry that includes the orbitofrontal cortex than by dorsolateral prefrontal cortex circuitry.

show abstract

“…Patients with major depression exhibit symptoms of sexual and cognitive dysfunction, which have been proven to be unrelated to minor depression and dysthesia (Murphy et al, 1998;Seidman and Roose, 2001;Airaksinen et al, 2004;Stordal et al, 2004). Alternatively, the sexual dysfunction in OB rats resembles the loss of interest that is a core symptom of depression.…”

Section: Discussionmentioning

confidence: 99%

“…Major depression is associated with cognitive impairments (Murphy et al, 1998;Airaksinen et al, 2004;Stordal et al, 2004). Studies have reported spared functions in depressed patients in tests tapping implicit memory (Hertel and Hardin, 1990;Danion et al, 1995), explicit memory (Bazin et al, 1994), and attention (Landro et al, 2001).…”

Section: Discussionmentioning

confidence: 99%

“…Major depressive patients exhibit significant cognitive dysfunction, to which minor depression is not related (Murphy et al, 1998;Airaksinen et al, 2004;Stordal et al, 2004). In the preconditioning phase of the test, all the rats showed a similar freezing time either in the neutral box or in the conditioning box (data not shown).…”

Section: Antidepressant-like Effects Of Sa-4503 In Ob Ratsmentioning

confidence: 91%

See 1 more Smart Citation

Role ofN-Methyl-D-aspartate Receptors in Antidepressant-Like Effects of σ₁Receptor Agonist 1-(3,4-Dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine Dihydrochloride (SA-4503) in Olfactory Bulbectomized Rats

Wang¹,

Noda²,

Tsunekawa³

et al. 2007

J Pharmacol Exp Ther

View full text Add to dashboard Cite

In the present study, we aimed to investigate the role of N-methyl-D-aspartate (NMDA) receptors in the antidepressant-like effects of a 1 receptor agonist, 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride (SA-4503), in the olfactory bulbectomized (OB) rat model of depression. A symptomatologybased behavioral investigation was made by reconstructing in OB rats the symptoms of depression, such as psychomotor agitation, loss of interest, and cognitive dysfunction, using a typical antidepressant, desipramine, as a positive control. Repeated treatment with SA-4503 ameliorated the behavioral deficits in OB rats resembling depression symptoms in the open-field test, sexual behavior test, and cued and contextual fear-conditioning test. SA-4503 displayed advantages over desipramine in the sexual behavior test. SA-4503 also reversed the decrease in the protein expression of NMDA receptor subunit (NR)1, but not NR2A or NR2B, in the prefrontal cortex, hippocampus, and amygdala of OB rats. The behavioral and neurochemical effects of SA-4503 were blocked by combined treatment with a specific 1 receptor antagonist, N,N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride (NE-100). Furthermore, the effects of SA-4503 on the performance of OB rats in the behavioral tests were abrogated by acute treatment with an NMDA receptor antagonist, (Ϫ)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801). The present study indicated for the first time that the 1 receptor agonist SA-4503 may have effects on depressive symptoms such as agitation, loss of interest, and impaired cognition, which are mediated by NMDA receptors.

show abstract

Cognitive Impairment in Depression: Psychological Models and Clinical Issues

Cited by 11 publications

References 81 publications

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines

The effects of tryptophan depletion on cognitive and affective processing in healthy volunteers

Role ofN-Methyl-D-aspartate Receptors in Antidepressant-Like Effects of σ₁Receptor Agonist 1-(3,4-Dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine Dihydrochloride (SA-4503) in Olfactory Bulbectomized Rats

Contact Info

Product

Resources

About

Cognitive Impairment in Depression: Psychological Models and Clinical Issues

Cited by 11 publications

References 81 publications

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines

The effects of tryptophan depletion on cognitive and affective processing in healthy volunteers

Role ofN-Methyl-D-aspartate Receptors in Antidepressant-Like Effects of σ1Receptor Agonist 1-(3,4-Dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine Dihydrochloride (SA-4503) in Olfactory Bulbectomized Rats

Contact Info

Product

Resources

About

Role ofN-Methyl-D-aspartate Receptors in Antidepressant-Like Effects of σ₁Receptor Agonist 1-(3,4-Dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine Dihydrochloride (SA-4503) in Olfactory Bulbectomized Rats